AbbVie Forecasts Strong 2026 Profit on New Drug Sales

AbbVie Projects Strong Profit Growth Through 2026

AbbVie has announced a 2026 profit forecast that surpasses Wall Street expectations. This optimistic outlook is supported by a strong fourth-quarter performance, primarily driven by its newer immunology drugs, Skyrizi and Rinvoq, and a smaller-than-expected decline in sales for its legacy drug, Humira.

Market Performance and Key Drivers

The pharmaceutical company is successfully managing the sales decline of Humira, which now faces competition from biosimilars after losing its patent exclusivity. The company's growth is being fueled by Skyrizi, with sales reaching $5.01 billion, and Rinvoq, with sales of $2.37 billion in the fourth quarter. Meanwhile, Humira's sales exceeded estimates despite a 25.9% drop.

Financial Outlook and Impact

AbbVie forecasts an adjusted annual profit per share between $14.37 and $14.57 for 2026, which is above the average analyst estimate of $14.24. For the fourth quarter, the company reported an adjusted profit of $2.71 per share, beating the consensus estimate of $2.65. This positive forecast signals a successful strategic shift toward its new product portfolio.

Summary and Future Trends

AbbVie's strategy to offset Humira's revenue loss with its newer drugs is proving effective. The strong financial results and forward-looking guidance suggest a stable growth trajectory for the company, which will be closely monitored by investors as it continues to execute its acquisition and expansion plans.

FAQ

Q: What is AbbVie's profit forecast for 2026?
A: AbbVie expects an adjusted annual profit per share to be between $14.37 and $14.57.

Q: Which drugs are driving AbbVie's current growth?
A: The primary growth drivers are the newer immunology drugs, Skyrizi and Rinvoq.

Source: Investing.com